ABSTRACT: Overtreatment is pervasive in medicine and leads to potential patient harms and excessive costs in health care. Although evidence-based medicine is often derided as practice by rote algorithmic medicine, the appropriate application of key evidence-based medicine principles in clinical decision making is fundamental to preventing overtreatment and promoting high-value, individualized patient-centered care. Specifically, this article discusses the importance of (1) using absolute rather than relative estimates of benefits to inform treatment decisions; (2) considering the time horizon to benefit of treatments; (3) balancing potential harms and benefits; and (4) using shared decision making by physicians to incorporate the patient's values and preferences into treatment decisions. Here, we illustrate the application of these principles to considering the decision of whether or not to recommend intensive glycemic control to patients to minimize microvascular and cardiovascular complications in type 2 diabetes mellitus. Through this lens, this example will illustrate how an evidence-based medicine approach can be used to individualize glycemic goals and prevent overtreatment, and can serve as a template for applying evidence-based medicine to inform treatment decisions for other conditions to optimize health and individualize patient care. 1 Overtreatment is pervasive in medicine and is not limited to a single therapeutic category.
O vertreatment is defined by the Institute of Medicine as the use of a treatment even when the potential harms exceed the possible benefits. 1 Overtreatment is pervasive in medicine and is not limited to a single therapeutic category. 2 Overuse, which encompasses both overtesting and overtreatment, accounts for ≈20% of the estimated $750 billion of wasteful spending in health care in the United States. 3 In addition, many physicians in the United States recognize that their own patients are receiving too much medical care that is potentially harmful. In a nationally representative survey, 42% of US primary care physicians thought their patients were receiving too much care in their own practices. 4 Even more were concerned about overly aggressive practice styles among medical subspecialists (61%).
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use both at the bedside and in guideline development and policy decisions to prevent overtreatment in their immediate spheres of influence. This review article will outline an EBM framework to guide clinical decision making to enable individualized medical treatment decisions concordant with the aims of patient-centered and personalized health care, increasing areas of national priority. 15, 16 WHAT IS EVIDENCE-BASED MEDICINE?
In the words of the late David Sackett, a founding father of evidence-based medicine, EBM is the "conscientious, explicit, and judicious use of current best evidence in making decisions about the care of individual patients." 17 The practice of EBM does not consist of universal, rote application of clinical guidelines. Rather, EBM requires physicians to assess and understand what the best available evidence is, use his or her clinical judgment to apply this knowledge to the treatment of individual patients, and do so in the context of the patient's values and preferences ( Figure 1) . Thus, the practice of EBM is not cookbook medicine, but is a complex and nuanced approach requiring mastery of 3 separate but overlapping domains of knowledge.
There are 2 key reasons why practicing EBM is not synonymous with the delivery of algorithmic cookbook medicine. First, many recommendations and guidelines are poorly substantiated by current evidence and, as such, should not be broadly disseminated and indiscriminately applied. 18 For example, among the American College of Cardiology and the American Heart Association practice guidelines issued between 1984 and 2008, only 11% of the 2711 recommendations were classified as level of evidence A (ie, supported by multiple randomized trials or a meta-analysis). 19 Furthermore, among the 1305 class I American College of Cardiology/American Heart Association guideline recommendations, which indicate general consensus that a particular healthcare service is useful and effective, only 19% have level of evidence A. 19 As such, ≈20% of class I American College of Cardiology/American Heart Association guideline recommendations were downgraded, reversed, or omitted within a decade, suggesting questionable durability in the absence of strong evidence. 20 The proliferation of recommendations on the basis of a weak or nonexistent evidence base is not only an issue for practice guidelines, but it is a phenomenon observed among popular online evidence-based resources. For example, approximately two-thirds of the 9400 graded recommendations in UpToDate are supported by weak evidence (ie, absence of clinical trials or robust observational studies). 18 The second and more compelling reason why EBM is not synonymous with cookbook medicine is that, even for recommendations on the basis of strong levels of evidence, decisions in clinical practice are still ultimately value judgements; ie, decisions ultimately hinge on the physician's and patient's assessment of whether or not a treatment is actually worth it after considering the potential harms and benefits enumerated in the scientific literature. 17, 18 Science can be used to inform clinical decisions, but cannot definitively inform value judgements, because the significance of potential benefits and harms of a therapy are in the eye of the beholder and will differ across individuals. Thus, the EBM triad requires a bottomup approach that incorporates the best available evidence with both the physician's expertise and judgment and the patient's values and preferences.
AN EBM APPROACH TO OVERCOMING OVERTREATMENT AND PERSONALIZING THERAPEUTIC DECISIONS
Distilled to its simplest form, an EBM approach provides guidance for making the best therapeutic decision for an individual patient through the understanding and application of 4 key principles:
1. Absolute estimates of benefit: What are the absolute (and not relative) benefits of a particular therapy for patient-centered outcomes? 2. Time horizon to benefit: How long must a patient be on a particular therapy to reap the potential benefit in comparison with their current life expectancy? 3. Balance of benefits versus harms: Do the potential absolute benefits outweigh the potential To illustrate how EBM principles should be applied to clinical decision making, we present the case example of considering whether to recommend intensive glycemic control in patients with type 2 diabetes mellitus, henceforth referred to as diabetes, to reduce microvascular and cardiovascular complications. Although using an EBM approach is not unique to specific diseases, diabetes is an ideal disease model to illustrate how an EBM approach can prevent the harms of overtreatment because: (1) diabetes is highly prevalent 21 ; (2) the strategy of intensive glycemic control has been thoroughly investigated, and there is a large body of evidence available on the benefits and harms of this treatment strategy; (3) the decision to pursue glycemic control is influenced less by external factors (ie, financial incentives and malpractice concerns) and more by physicians' clinical decision making in comparison with other conditions (eg, percutaneous coronary intervention for stable angina) 22, 23 ; and (4) applying an EBM approach to the treatment of hyperglycemia in type 2 diabetes highlights the discordance between the current prevailing paradigm of treatment versus what is actually supported by the best available current evidence.
ASSESSING THE ABSOLUTE ESTIMATES OF TREATMENT BENEFIT FOR PATIENT-CENTERED OUTCOMES
To understand why absolute estimates of benefit are the preferred measure of treatment efficacy, it is first necessary to understand the limitations of relative risks. Imagine a hypothetical trial assessing the benefit of drug X versus placebo in preventing myocardial infarction over a 1-year treatment period. If the outcome occurs in 10% of individuals on drug X (risk 1) versus 15% taking placebo (risk 2), the relative risk (RR) of a myocardial infarction for individuals prescribed drug X is 0.67 (risk 1/risk 2) and the corresponding relative risk reduction (RRR) is 33% (100×(1-RR)). In this example, the absolute risk reduction (ARR) for myocardial infarction among individuals treated with drug X is 5% (risk 2-risk 1) and the number needed to treat (NNT) is 20 (1/ARR). For this same hypothetical trial, if the risk of myocardial infarction for those prescribed drug X is only 1% and the risk in the placebo group is only 1.5%, the RR remains a deceptively impressive 0.67; but the ARR is now only 0.5%, and the NNT is 200, indicating a minimally effective therapy. Thus, reports of the RR or RRR do not provide physicians any information on the magnitude of treatment benefit. Relying on these measures alone makes it impossible to assess the clinical relevance of the treatment and may lead to erroneously inflated estimates about the potential benefit.
In contrast, absolute estimates of treatment benefit in the form of ARR or NNT more accurately convey the treatment effect size and potential clinical significance of treatment. In the hypothetical trial above, a NNT of 20 means that one would need to treat 20 individuals (with characteristics within the parameters of the trial's inclusion and exclusion criteria) with drug X for 1 year to prevent 1 additional myocardial infarction in comparison with placebo. It is notable that a NNT of 20 also implies that, for every 20 people treated with drug X, on average, 19 people derive no benefit with respect to preventing a myocardial infarction in comparison with being prescribed placebo over this time period. Although both the ARR and NNT are valid measures to convey the absolute benefit of therapy, the NNT more clearly illustrates that the benefits of treatment are not shared equally by every individual in the treatment group, and that most individuals in this example will not derive any benefit after 1 year of therapy, even for what many would consider a clinically meaningful effect size.
There are important limitations to the interpretation and application of absolute risks. First, absolute risks are estimated at the population level. As the evolutionary biologist, Stephen Jay Gould, astutely stated in his essay, The Median Isn't the Message, "variation is the hard reality, not a set of imperfect measures for a central tendency." 24 Thus, ARR and NNT convey average estimates of benefit in a group and cannot predict the potential benefit for an individual patient. Physicians must therefore also consider an individual's risk profile for the outcome of interest on the basis of established risk factors. Assessing the potential benefits (and harms) of treatment in the context of individuals' risks is essential to the optimal selection of individuals for treatment. Second, treating individuals who are either healthier or sicker than those included in studies can significantly alter the harm-benefit profile of a therapy. 25 This phenomenon, commonly referred to as indication drift, can markedly reduce the effectiveness of therapies. Last, absolute measures of risk (and relative risks, as well) are estimated only for specific durations of time on treatment and, as such, do not capture the full effect of time. 26 Consequently, ARR and NNT provide limited information to guide treatment decisions beyond the duration reported in clinical studies. Despite these limitations, the absolute risk is essential to understanding the magnitude of potential benefit, and is the first step 27 Other trials have similarly failed to show improvement in these more clinically meaningful end points. 32, 33 The evidence for the relative benefits of intensive glycemic control for preventing cardiovascular disease is even less well substantiated. Although the benefits for reducing surrogate microvascular outcomes have been consistently observed in trials, 31 [27] [28] [29] [30] 35 the results of a meta-analysis more clearly supported this 15% relative reduction. 31 However, it should be noted that intensive glycemic control has not been shown in parallel to also reduce cardiovascular disease-specific mortality (RR, 1.11; 95% confidence interval [CI], 0.86-1.43) or all-cause mortality (RR, 1.04; 95% CI, 0.91-1.19), calling into question the reliability and significance of the reduced risk in nonfatal MIs. 31 In addition, intensive glycemic control does not reduce the risk of strokes. 36 Thus, although diabetes remains a strong prognostic marker for cardiovascular disease, achieving intensive glycemic control does not modify the risk of cardiovascular disease.
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It is noteworthy that 2 recent multicenter diabetes outcomes trials of empagliflozin and liraglutide demonstrated clinically significant reductions in both cardiovascular disease-specific and all-cause mortality. 37, 38 Although potentially representing important advances in the therapy of type 2 diabetes, the observed mortality reduction in these trials was likely not mediated through the mechanism of intensive glycemic control for several reasons. First, although not explicitly designed to test the effect of intensive glycemic control, there was only a modest reduction in HbA 1c of 0.4% in comparison with ≈1% reduction achieved in other trials, none of which showed reductions in cardiovascular or all-cause mortality. 31, 37, 38 Second, the modest 37 to nonexistent reductions 38 in large vessel atherosclerotic-mediated cardiovascular outcomes (MIs and strokes) were disproportionately smaller in magnitude than the observed reduction in cardiovascular disease-specific mortality in these trials. These results suggest that these medications may be working through mechanisms other than preventing the progression of atherosclerosis, which is the implicated causal pathway between hyperglycemia of diabetes and cardiovascular disease-specific mortality. 39 Last, the improvement in cardiovascular mortality in both of these trials emerged far earlier than expected (within the first 3 months for empagliflozin and 6 months for liraglutide) given the natural history of the progression of atherosclerosis attributable to hyperglycemia. 39 Taken together, these trials suggest that the reductions in mortality observed with these medications are not attributed to intensive glycemic control, but rather are attributable to medication-specific effects on other unidentified mechanistic pathways.
Modest Absolute Benefits of Intensive Glycemic Control for Diabetes
There is no direct evidence of an absolute benefit of intensive glycemic control on patient-centered outcomes such as clinically apparent microvascular disease or mortality despite several well-conducted clinical trials with up to 15 years of follow-up. 33 Consequently, to estimate the absolute benefits of glycemic control, we must rely instead † Surrogate outcome defined as loss of both ankle reflexes or both knee reflexes, or mean biothesiometer reading from both toes >25 V.
‡ Surrogate outcome defined as urinary albumin concentration >50 mg/L.
on simulation studies that model the potential benefits of glycemic control on clinical outcomes, extrapolating the observed effects on intermediate outcomes from landmark trials over a much longer timespan than is feasible in those trials. This approach represents the best available evidence regarding the absolute benefits of intensive glycemic control with respect to clinically relevant outcomes that patients and physicians care about. To this end, Vijan and colleagues 40 developed a Markov simulation model to estimate the absolute benefits of intensive glycemic control using simulated individuals with characteristics on the basis of adults with diabetes sampled in the National Health and Nutrition Examination Study (NHANES), a nationally representative population survey in the United States. The authors modeled the risk of progression from the onset of asymptomatic diabetes to intermediate microvascular outcomes and the cardiovascular outcome of nonfatal MI using the RRRs with intensive glycemic control observed in clinical trials ( Table 1 ). The authors then estimated the likelihood of progression from these intermediate outcomes to end-stage complications (eg, visual loss, amputation, endstage renal disease) and death by using findings from other randomized controlled trials and US population-based observational studies. [41] [42] [43] [44] [45] [46] Using this model, the authors simulated 2 treatment scenarios commonly encountered in clinical practice to estimate the absolute benefits of intensive glycemic control on clinically apparent microvascular and cardiovascular complications of diabetes. The first scenario assesses the benefit of lifelong oral pharmacotherapy to achieve intensive glucose control. It consists of a person newly diagnosed with diabetes with an HbA 1c of 8.5% who is prescribed metformin and experiences a reduction in the HbA 1c level of 1.5 points to 7.0%, which remains at this level over the course of the person's life. The second scenario assesses the benefit of augmenting an oral pharmacotherapy regimen with insulin. In this scenario, insulin therapy is initiated for the same patient in the first treatment scenario after the failure of 10 years of oral antihyperglycemic therapy with a rise in HbA 1c level back to 8.5%. Insulin therapy reduces the HbA 1c level to 7.5% and remains at this level over the remainder of the person's life. The lifetime absolute benefits of intensive glycemic control for each scenario, depending on the age at which diabetes is initially diagnosed, are shown in Figure 2 . In both scenarios, the potential benefit of intensive glycemic control greatly declines with the age at which an individual is diagnosed. For an average 75-year-old with newly diagnosed diabetes initiating metformin (Figure 2A ), the NNT for preventing end-stage renal disease (ESRD), vision loss, and amputation over that person's lifetime are 143, 200, and 125, respectively. For an average 55-year-old in whom oral antihyperglycemic therapy failed and who was subsequently initiated on insulin 10 years later for uncontrolled diabetes (HbA 1c of 8.5% on oral therapy), the NNT values are well above 100 for each microvascular end point ( Figure 2B ). In other words, >99% of adults ≥65 years of age initiated on insulin therapy to achieve intensive glycemic control will not derive any benefit with respect to clinically apparent microvascular complications within their lifetime.
Although the NNT for preventing nonfatal MIs is considerably more favorable than for preventing patient-centered microvascular outcomes across all age groups for both scenarios, the confidence behind these estimates is limited because of the increase in cardiovascular mortality observed in the ACCORD trial (Action to Control Cardiovascular Risk in Diabetes), and the nonsignificant increase seen in meta-analyses, as well. 28, 34, 36 These findings illustrate the stark differences in using relative versus absolute risks to inform treatment decisions. Even when RRRs for surrogate microvascular and cardiovascular outcomes are the same across individuals, the absolute risk reductions for corresponding clinically meaningful outcomes may be vastly different for individuals with different baseline risk profiles and life expectancies. Relying on RRs can vastly overestimate the benefits from treatment, which is why absolute risks are the preferred method to inform therapeutic decisions.
ASSESSING THE TIME HORIZON TO BENEFIT FOR INTENDED THERAPIES
As discussed above, a major limitation of absolute measures of risk is that they do not capture the full effect of time. Rather, absolute measures of risk quantify the benefits of treatment in a given time period. Consequently, absolute measures of risk cannot be used to quantify the potential benefits of postponing an outcome. For example, consider a hypothetical trial of adults with a 100-year follow-up period where the primary outcome is mortality. Because adult human life expectancies rarely exceed 100 years, all trial subjects will die within the follow-up period irrespective of any intervention aimed at reducing mortality in this study. Thus, the observed absolute risk reduction for the intervention will be 0 (with a NNT of infinity) at the conclusion of the trial. In this extreme example, relying solely on the ARR or NNT as measures of effect size may fail to capture a potential benefit of treatment if therapy postponed the inevitable outcome of death for a clinically meaningful amount of time (eg, perhaps subjects receiving the intervention postponed death by 10 years, even if they inevitably died within the 100-year follow-up period).
Similarly, absolute measures of risk also do not consider the time horizon to benefit, that is, the time that must be accrued on treatment until a meaningful benefit emerges. This is a more commonly encountered issue than postponement of an outcome because study follow-up periods tend to be limited in duration. For a treatment with a sufficiently long time horizon to benefit, individuals with a life expectancy less than the time horizon to treatment benefit will not reap the potential benefits of treatment. Thus, these individuals will be exposed to the potential upfront harms of therapy without any chance of benefit, a classic scenario of overtreatment. To avoid these potential harms, only individuals whose anticipated life expectancy exceeds the estimated time horizon to benefit should be considered as candidates for treatment.
The time horizon to benefit can be estimated from clinical studies by calculating the difference in the area under the survival curves, although these measures are infrequently quantified and reported. Alternately, the time horizon to benefit can be qualitatively estimated by assessing Kaplan-Meier survival curves for the intervention and control groups to identify the point at which the 2 curves diverge. 47 This divergence point provides an estimate of the minimum time horizon to benefit for a given treatment. To illustrate how to estimate the time horizon to benefit by using survival curves and understand its implications, we will return to the example of diabetes.
Time Horizon to Benefit for Intensive Glycemic Control in Diabetes
On the basis of the Kaplan-Meier curve from the UKPDS trial (United Kingdom Prospective Diabetes Study), it takes ≈9 years of intensive glycemic control to yield an observable reduction in composite microvascular events in the treatment group (vertical dashed line in Figure 3 ). However, it is important to note that the composite microvascular outcome reported in the UKPDS trial consists mostly of intermediate outcomes that may not directly harm patients (ie, need for photocoagulation, vitreous hemorrhage, or renal failure defined as an elevated creatinine >2.8 mg/dL). The potential for intensive glycemic control to prevent more meaningful microvascular outcomes (ie, vision loss or ESRD requiring dialysis) is estimated to take ≥2 decades to manifest. 48 Of note, even with an additional 10 years of follow-up in the UK-PDS trial (for a total of 25 years), improvements in these end points have not yet been reported. 49 This suggests that the legacy effect observed for surrogate microvascular end points seen after a decade of early intensive glycemic control in patients with newly diagnosed diabetes may not translate into reductions in patient-centered microvascular outcomes.
Despite the long time horizon to benefit for intensive glycemic control, many patients prescribed intensive glycemic control nonetheless have life expectancies of <20 years, and potentially even <9 years, the earliest time interval after which one could expect to observe benefits for intermediate microvascular outcomes. 50 This is a clear example of overtreatment: individuals who are initiated on intensive glycemic control who have a life expectancy of <9 years are exposed to the potential harms of treatment without any reasonable chance of benefit. Consequently, a pragmatic approach to avoiding the harms of overtreatment would be to defer intensive glycemic control in individuals with a life expectancy that is clearly <9 years. For example, individuals with advanced cancers, ESRD, advanced dementia, cirrhosis, and end-stage heart failure and lung disease are unlikely to benefit from intensive glycemic control.
There are also several highly prevalent but less commonly recognized conditions that also indicate poor prognosis and limited life expectancy. After a first hos- Figure 2 . Estimated lifetime absolute benefits of intensive glycemic control for preventing microvascular outcomes.
A, Treatment Scenario 1: initiation of metformin at diagnosis, with HbA 1c reduction from 8.5% to 7.0%. B, Treatment Scenario 2: initiation of insulin 10 years after failing initial oral therapy, with HbA 1c reduction from 8.5% to 7.5%. The number needed to treat values were calculated from the estimated absolute risk reductions on the basis of Vijan and colleagues' Markov simulation model. 40 For scenario 2, the absolute risk reduction for prevention vision loss among 75-year-old patients with new-onset diabetes was 0%, thus yielding a number needed to treat of infinity. ESRD indicates end-stage renal disease; and MI, myocardial infarction.
pitalization for heart failure with either preserved or reduced ejection fraction, individuals have a 70% 5-year mortality rate. 51, 52 Likewise, after the first hospitalization for chronic obstructive pulmonary disease exacerbation, individuals have an 80% 9-year mortality. 53 Thus, initiating intensive glycemic control during or after an index hospitalization for either heart failure or chronic obstructive pulmonary disease is unlikely to yield any benefit beyond that of a conventional glycemic control strategy.
Individuals with multimorbidity and impaired functional status also have limited life expectancy because of the cumulative burden of illness, although prognosis can be challenging to assess in these complex patients. The Lee Schonberg Index 54 is a validated tool that quantifies the 4-year and 10-year risk of mortality among community dwelling adults 50 years of age or older. 55, 56 This index assesses the cumulative contribution of age, selected comorbidities and health behaviors (diabetes, cancer, heart disease, lung disease, body mass index<25, and current smoker), and impairments in functioning (bathing, managing finances, ambulating, and pushing or pulling heavy objects) on the risk of mortality using a point score ranging from 0 to 25, with higher scores corresponding to higher risk of death. The Lee Schonberg Index has excellent discrimination (C-statistic of 0.83) and calibration (<4% difference between predicted and observed mortality rates across all risk levels). 56 In a nationally representative longitudinal cohort, the Lee Schonberg Index identified that 25% of communitydwelling individuals ≥50 years of age have a >50% risk of death within 10 years. 56 Thus, 1 in 4 middle-aged and older adults in the United States are unlikely to live 10 years, let alone 20 years, to reap the benefits of intensive glycemic control. This is reflected in the exceedingly low lifetime absolute benefits for intensive glycemic control estimated for individuals who have high point scores on the Lee Schonberg Index. In a decision analysis study, Huang and colleagues 57 developed a simulation model on the basis of data from the UKPDS trial and found that, among older adults with diabetes, those with greater multimorbidity and functional impairment are far less likely to benefit from intensive glucose control. For example, for individuals aged 60 to 64 years who have new-onset diabetes and only 1 point on the Lee Schonberg Index, the NNTs to prevent ESRD, blindness, and amputation over one's lifetime are approximately 125, 83, and 77, respectively. In contrast, the lifetime NNT for the same scenario, with the exception of patients who have significant multimorbidity and functional impairment (Lee Schonberg Index score of 15 points), are infinity (ARR of 0%), 2700, and 1125, respectively. 57 Thus, only the few older adults with diabetes and almost no functional limitations will derive benefit from intensive glucose control. Those with substantial multimorbidity and functional limitations have an infinitesimally small probability of deriving any benefits from this treatment strategy.
ASSESSING THE BALANCE BETWEEN POTENTIAL BENEFITS VERSUS HARMS OF TREATMENT
Overtreatment may arise when one focuses only on the benefits of therapy without any consideration of potential harms, because this would lead to always favoring treatment even if the benefit of treatment is extremely small. Thus, it is critical to understand and assess the potential harms of treatment, and to incorporate this knowledge into treatment decisions. The potential harms of therapy are quantified through estimates of the absolute risk increase and the number needed to harm (NNH) for specific adverse effects related to treatment. Awareness of both the NNT and NNH for a given treatment can help physicians and patients alike make more informed decisions about whether the potential for benefits is worth taking the risks.
There are several challenges in assessing the balance between the NNT and NNH for treatments. First, because each individual beneficial or harmful effect will have varying impact on quality of life, it may be difficult to directly compare benefits and harms. Consider, for example, the potential benefit of preventing a stroke versus the potential harm of causing a bleed with anticoagulation therapy for atrial fibrillation. In comparison with major bleeding, having a stroke is considered more detrimental to quality of life because major bleeding is more likely to be transient and reversible than neurological deficits from a stroke. 58 Second, treatments may have a myriad of beneficial and harmful effects; consequently, it can be difficult to simultaneously assess the net balance of benefits The composite microvascular end point was defined as retinopathy requiring photocoagulation, presence of vitreous hemorrhage, and fatal or nonfatal renal failure defined as an elevated creatinine >2.8 mg/dL. Reprinted from UK Prospective Diabetes Study (UKPDS) Group 27 with permission of the publisher. Copyright ©1998, Elsevier.
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and harms. Third, the NNT and NNH are reported for selected benefits and harms that are discrete in nature (ie, present or absent), and are not designed to take into account the effect of treatment on other measures of quality of life (ie, treatment burden) that are also important to patients. By only considering the value of treatment by the NNT and NNH, important information may be lost on other dimensions of therapy.
An approach to overcome these limitations is to quantify the balance between the potential benefits and harms of therapy by estimating the net quality-adjusted life-years (QALYs) associated with treatment. This measure of overall health impact incorporates both the quantity and quality of life related to all potential benefits and harms of therapy. QALYs integrate the general quality of life on a scale from 0 to 1, with values closer to 1 indicating higher quality of life, on the basis of an individual's probability of being in various disease and treatment complication states each year. 59, 60 Estimated QALYs, when available, can thus allow for direct comparisons of health impact between different treatments.
In the absence of studies evaluating the net QALYs gained from therapy, the NNT can be used to estimate the magnitude of benefit for a treatment. Acknowledging that the NNT does not fully account for many factors, including the clinical significance of the outcome (ie, microalbuminuria versus ESRD), the cost, convenience, and invasiveness of the therapy (ie, metformin versus insulin), and the NNH for various adverse effects, one may roughly interpret that a NNT >15 is associated with a small net treatment benefit, and a NNT ≤5 is typically associated with a meaningful net benefit. 61 
Balancing the Harms and Benefits of Intensive Glycemic Control in Diabetes
With respect to diabetes, there are several important potential harms to consider before prescribing antihyperglycemic therapy. Although risks are unique to each therapy, the most common side effects of intensive glycemic control reported in clinical trials were severe hypoglycemia and weight gain, both attributable to higher rates of insulin use among these patients. 31, 33 Severe hypoglycemia occurred in 4.9% of those on intensive glycemic control versus 2.0% among those on conventional glycemic control (absolute risk increase of 2.9%; NNH of 35). 31 In addition, intensive glycemic control increased body weight by ≈3%. 33 Another important but often overlooked harm of intensive glycemic control is the potential decrease in a person's overall quality of life because of the burden of the treatment itself. Because of the burden of polypharmacy, multiple insulin injections, frequent blood glucose monitoring, and increased frequency of healthcare visits, an intensive glycemic control strategy per the UKPDS trial protocol was perceived by individuals to have a median quality-of-life utility value of 0.85 (mean, 0.67±0.34) on a scale where perfect health is 1 and death is 0. 62 A utility of 0.85, also referred to as a disutility of 0.15, means individuals equate living 10 years with intensive glycemic control the same as living 8.5 years in perfect health. It is notable that the decrease in quality of life attributable to intensive glycemic control is perceived by patients to be of the same magnitude as that attributable to a mild stroke (Figure 4) .
To balance the potential benefits of intensive glycemic control with the potential harms, Vijan and colleagues 40 used a Markov simulation model as described previously to estimate the net lifetime QALYs gained with therapy. The authors assigned quality-of-life utility values to each disease state along the spectrum from asymptomatic diabetes to death on the basis of prior literature to estimate net QALYs gained or lost. 40, 63, 64 The overall treatment burden was estimated across a range of disutilities for intensive glycemic control for a scenario where an individual was prescribed a pharmacological therapy that reduced the HbA 1c from 8.5% to 7.5%. In this scenario, treatment burden has a profoundly detrimental impact on the net QALYs gained from treatment ( Figure 5 ). If an individual experiences no treatment burden whatsoever (ie, a treatment burden of 0), antihyperglycemic therapy in this scenario would yield only modest net benefits across all 4 age groups with a net lifetime gain of 0.9 QALYs for an average 45-year-old patient to 0.1 QALYs for an average 75-year-old patient. However, a treatment burden as little as 0.04 negates any benefit of intensive glycemic control for all age groups, and actually results in loss of quality of life. Therefore, the value of intensive glycemic control depends on an individual's experienced or perceived treatment burden.
These findings should be interpreted in the context of certain limitations. First, the authors' optimistic assumptions of a 15% risk reduction in nonfatal MI events and Median quality-of-life utility values for various treatments and complications were derived from Huang et al. 62 The orange bars for intensive glucose control and mild stroke are added for emphasis to highlight that, on average, patients perceive these different states as having the same magnitude in the decrease in quality of life.
relatively low estimates of treatment disutilities (capped at 0.05, much lower than the previously reported median disutility of 0.15 for intensive glycemic control in Figure 4 ) biases the results in favor of intensive glycemic control. The actual net loss in quality of life is likely to be greater than this study suggests. Second, as discussed earlier, the net benefits of intensive glycemic control are estimated for the average patient for each age group. Individuals with greater risk for microvascular and cardiovascular disease (eg, tobacco use, hypertension, high cholesterol) in comparison with the average patient with diabetes (mean blood pressure of 130/80 mm Hg and mean low-density lipoprotein cholesterol of 100 mg/dL) 65 are more likely to derive benefits from intensive glycemic control. However, individuals with a lower than average risk profile will have even less to potentially gain from therapy than the modeled scenarios suggest.
ASSESSING WHETHER TREATMENT IS CONSISTENT WITH PATIENT VALUES AND PREFERENCES: SHARED DECISION MAKING
Shared-decision making (SDM) is defined as a partnership between physicians and patients to make preference-sensitive decisions together, guided by the best available evidence and the patient's risks, prognosis, and sociopersonal context. 66 Preference-sensitive therapeutic decisions indicate that there is clinical equipoise regarding ≥2 treatment options, such that a person's values and preferences can meaningfully shift the decision toward 1 therapeutic option. SDM is not indicated for every clinical decision. For decisions where there is overwhelming support for a particular treatment such that the benefits clearly outweigh the harms (ie, insulin in diabetic ketoacidosis), a more parentalistic model of decision making is preferred.
There are 4 key steps to implementing SDM in clinical practice: (1) explain to the individual that there is clinical equipoise with respect to how best to treat the disease; (2) present information on the different choices on the basis of the best available evidence; (3) support deliberation between the various therapeutic choices by discussing the person's values and their sociopersonal context (eg, lifestyle, social support, financial means, workload capacity) to effectively implement different treatments; and (4) formulate a decision (Table 2) . [66] [67] [68] For SDM to be effective, physicians must both provide information in an unbiased manner and support the decision-making process. In a population-based survey in the United States, nearly everyone (96%) reported that they would like to be offered choices and to participate in the decisionmaking process (steps 1-3 above); however, half of respondents preferred their physician to make the final decision (step 4). 69 In these situations, a physician can still engage individuals in SDM through empathic conversation, followed by choosing a therapeutic option that best matches the person's values and the individual's "effort, time, and energy to effectively implement treatment within their lives and routine." [70] [71] [72] The practice of SDM has many benefits, including improving patient's knowledge regarding treatment options, reducing patient decisional conflict, stimulating patients to take a more active role in the decision-making process, and leading patients to make more conservative treatment choices than their physicians. 73, 74 For example, among patients with stable coronary disease, more complete SDM discussions were strongly associated with fewer patients choosing to undergo angiography and possible percutaneous coronary intervention. 74 Despite these benefits, the practice of SDM is suboptimal in current clinical practice, with few physicians providing a balanced explanation of the pros and cons of therapeutic options, and fewer exploring patients' preferences and values. [74] [75] [76] This may be in part because implementing SDM in clinical practice is challenging, and because the optimal strategies for the practice of SDM have yet to Net lifetime quality-adjusted life-years gained or lost by a treatment that leads to a 1% reduction in the hemoglobin A 1C level (from 8.5% to 7.5%) across 4 age groups and different views of the burden of treatment (disutility value for treatment ranging from 0 to 0.05). Reproduced with permission from Vijan et al 40 with permission of the publisher. Copyright ©2014, American Medical Association.
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be identified and represent a growing area of research. To facilitate SDM, the use of decision aids (either in electronic, pamphlet, or video format) can help clarify the decision, present evidence-based information regarding the potential benefits and harms of different therapeutic options, and elicit patient's values. 73 The use of visual aids, such as icon arrays, have been shown to improve a patient's understanding of probabilistic information on the benefits and harms of treatment. 77 
SDM in Diabetes
Given the very modest potential gains from antihyperglycemic treatment (Figure 2) , an individual's treatment burden can potentially negate any benefit gained from intensive glycemic control ( Figure 5 ). Consequently, there is clinical equipoise regarding treating to an HbA 1c of 6.4% to 7.0% among adults with diabetes. Thus, it is essential to elicit patients' values, preferences, and sociopersonal context and use this information to make treatment decisions. To translate the principles of shared decision making into a pragmatic clinical model, we outline a SDM approach in Table 2 through the lens of a treatment decision scenario of whether or not to initiate insulin. This SDM model is informed by the conceptual framework by Charles and colleagues, and extends on principles from 2 other pragmatic SDM approaches. [66] [67] [68] 78 To our knowledge, no decision aid for setting glycemic goals in diabetes currently exists. However, once the decision has been made to treat diabetes, the Diabetes Medication Choice Decision Aid 79 can help physicians prescribe the optimal medication that best aligns with the patient's preferences and sociopersonal context, 72, 80 because the best available evidence shows that there are no meaningful differences between the available antihyperglycemic drugs for reducing cardiovascular or all-cause mortality. 81 
OVERTREATMENT IN TYPE 2 DIABETES
Current evidence strongly supports that there is a potential epidemic of overtreatment with antihyperglycemic Step 1: Explain Equipoise
Step 2: Present Information
Step 3: Support Deliberation by Empathic Conversation
Step 4: Formulate a Decision 82 As of 2012, >50% of people with diabetes have achieved HbA 1c levels <7%, which by standard convention is considered well controlled ( Figure 6 ). However, achieving tight glycemic control is not an end in and of itself, and may represent overtreatment if the patients who have achieved HbA 1c levels <7% have minimal potential for benefit, are exposed to greater risk of harm, or have life expectancies shorter than the time horizon to benefit.
A closer examination of the data indeed shows that many of these individuals who have achieved tight glycemic control are likely being overtreated; those with the most potential for harm and the least potential to benefit are being treated too intensively. Using NHANES data, Lipska and 83 Furthermore, among these 1.8 million older adults, ≈60% are using insulin or sulfonylureas, 2 classes of antihyperglycemic therapies with the greatest potential for harms. 83 This implies that many of these multimorbid and frail older adults are unlikely to experience the potential benefits of intensive glycemic control, but nonetheless are exposed to the potential harms of therapy, including hypoglycemia and decreased quality of life attributable to the treatment burden itself.
In the Veteran Affairs healthcare system the pattern of overtreatment is similar. Approximately 50% of older veterans who are prescribed insulin or a sulfonylurea and are at high risk for hypoglycemia (≥75 years of age; serum creatinine ≥2 mg/dL; or dementia) have achieved HbA 1c levels <7%. 84 Although the authors were unable to assess the rate of severe hypoglycemia in this highrisk cohort, others have shown that hospitalizations for hypoglycemia among older adults with diabetes are now more common in the United States than hospitalizations for hyperglycemia (105 versus 70 admissions per 100 000 person-years), 85 with patients with the lowest HbA 1c levels being at greatest risk. 86 Last, in a national cohort of >30 000 individuals with diabetes enrolled in private and Medicare Advantage insurance plans in the United States, ≈20% of those with a HbA 1c level <7% were individuals with advanced clinical complexity (≥75 years of age, or high comorbidity burden) who nonetheless received intensive antihyperglycemic therapy. These individuals had nearly double the probability of severe hypoglycemia (3.0%) in comparison with those receiving standard antihyperglycemic therapy The current paradigm of glucose management in type 2 diabetes is to classify adults as being controlled (solid shaded gray area) if the hemoglobin A 1C level is <7%, and uncontrolled if the hemoglobin A 1C level is >7% (solid shaded light gray area). Because this classification does not define whether treating glucose to lower levels is beneficial for an individual patient, we propose classifying diabetes as asymptomatic and symptomatic (shaded areas indicated by dashed lines), such that, for asymptomatic patients, a shared decision-making discussion between the patient and clinician should occur first before reflexively treating glucose to lower levels. Although we dichotomize this distinction at 9% at the population level, patients may have symptoms related to hyperglycemia at lower values of hemoglobin A 1C . NHANES indicates National Health and Nutrition Examination Survey.
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(1.7%). 87 Taken together, these data suggest that we, as a collective profession, are substantially overtreating diabetes without regard for absolute benefits, harms, or time horizon to benefit.
Aside from making the appropriate initial recommendation of whether or not to pursue intensive glycemic control, another approach to overcoming overtreatment of diabetes is to deintensify antihyperglycemic medications when HbA 1c levels are at or below goal by either reducing medication doses or discontinuing therapy altogether if warranted. However, medication deintensification is uncommon in clinical practice. Among older veterans who are actively being treated for diabetes, medication deintensification rates are fairly low (<30%), even among patients with extremely tight glycemic control (HbA 1c levels <6%) and limited life expectancy, as predicted by multimorbidity and age. 88 There are several reasons for this clinical inertia. First, a substantial proportion of physicians believe that intensive glycemic control is beneficial even among older adults at high risk for adverse effects. In a national survey of primary care physicians, ≈40% believed that a hypothetical older adult with diabetes at high risk for hypoglycemia (HbA 1c of 6.4%, chronic kidney disease, and treated with a sulfonylurea) would benefit from an HbA 1c level <7.0%. 89 Similarly, almost half of providers (45%) worried that this individual would be harmed by an HbA 1c level >7.0%. 89 Second, practice guidelines for diabetes focus primarily on glycemic goals and have been slow to incorporate EBM and patient-centered principles into revised recommendations. In the 2015 American Diabetes Association Standards of Medical Care in Diabetes (93 pages) and the American Diabetes Association and European Association for the Study of Diabetes position statement (20 pages), there was not a single mention of the absolute magnitude of potential harms or benefit of intensive glycemic control. 90 Furthermore, practice guidelines for diabetes are relatively blind to context. In a review of 28 different practice guidelines for setting glycemic goals in type 2 diabetes, only 60% considered comorbidities, 40% considered sociopersonal context (eg, financial means, caregiver support), and 40% considered patient preference. 91 Overall, the synthesis of best available evidence to incorporate information on absolute benefits and harms and on patient preferences remains suboptimal, and may unintentionally lead to uniform rather than personalized application of glycemic control goals to patient care, even when the harms of therapy outweigh the potential benefits in many individuals with diabetes.
CONCLUSION: AN EBM APPROACH IS NEEDED TO PREVENT OVERTREATMENT
In summary, Figure 1 illustrates an EBM framework that can be used for clinical decision making to inform treatment decisions. To promote personalized care and overcome overuse, it is essential to incorporate best available evidence (balancing absolute harms and benefits, while incorporating the time horizon to benefit) with the physician's judgment (individualizing the evidence on the basis of a patient's risk profile, prognosis, and context) and the patient's preferences and values (via shared decision making). What EBM does not entail is eschewing clinical significance and patient preferences for statistical significance, nor does it entail the uniform application of therapies on the basis of measures of average population tendencies, especially when the level of evidence is weak. In contrast, an EBM approach calls for making personalized treatment recommendations with full consideration given to a patient's individual sociopersonal context and values.
Applying this EBM framework to the example of managing hyperglycemia in type 2 diabetes highlights the clinical equipoise in setting glycemic goals for diabetes, that no single HbA 1c level is appropriate for all patients. As such, we should abandon the notion that HbA 1c levels ≤7% are well controlled and levels > 7% are uncontrolled. This arbitrary dichotomy does not adequately portray whether we are optimizing the benefits of treatment, quality of life, and value for individuals, because most people with diabetes in the uncontrolled range (ie, HbA 1c >7%) are nonetheless asymptomatic (Figure 6 ), and achieving tight glycemic control does not meaningfully reduce cardiovascular complications. Rather, an EBM approach would consist of treating to achieve adequate glycemic control to prevent symptomatic disease (eg, polyuria, polydipsia), followed by further consideration of more intensive treatment if a clinical assessment suggests that the potential absolute benefits outweigh the harms, as with any other cardiovascular risk factor. This assessment would encompass a thorough understanding of the patient's risks, prognosis (ie, age, comorbidities, and functional status), and socio-personal context (eg, lifestyle, social support, workload capacity), as well as engaging with the patient to elicit perceived or experienced treatment burden, and values and preferences for care. Above all else, it is imperative for physicians to remember that the fundamental goal is to help individuals who have diabetes make the best therapeutic decision to improve their overall health and quality of life, not to prevent diabetes-related complications by any means possible.
The EBM approach we present here is not limited to the consideration of intensive glycemic control in type 2 diabetes, but, rather, is intended to serve as a framework to inform treatment decisions more broadly. Furthermore, this EBM framework also enables physicians to directly advance the overall goal of the national precision medicine initiative, to individualize treatments to achieve the best health outcomes for each person. 15 To achieve this goal, further advances in genomics and other biomedical knowledge will undoubtedly be instrumental; however, physicians currently have the tools available at their disposal to personalize care for many important treatment decisions without further medical innovation. As such, the purpose of this review is a call to action for physicians, medical educators, researchers, and policy leaders to apply the principles of EBM to individualize treatment decisions to optimize the health and well-being of patients.
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